Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: BMS is a global pharmaceutical and healthcare company organized into three reportable segments: Pharmaceuticals, Nutritionals, and Other Health Care. The company focuses on the discovery, development, and commercialization of pharmaceuticals and related health care products.
Key Financial Metrics
| Metric (in millions) | Three Months Ended Sep 30, 2007 | Nine Months Ended Sep 30, 2007 |
|---|---|---|
| Net Sales | $5,050 | $14,454 |
| Net Earnings | $858 | $2,254 |
| Earnings Per Share (Diluted) | $0.43 | $1.14 |
| Operating Cash Flow | $700 (approx. for quarter) | $2,523 |
| Cost of Products Sold Margin | 32.1% of Net Sales | 31.6% of Net Sales |
| Effective Tax Rate | 24.2% | 19.7% |
| Short-Term Borrowings | $1,879 | $1,879 (as of Sep 30) |
| Long-Term Debt | $4,248 | $4,248 (as of Sep 30) |
| Cash and Cash Equivalents | $1,647 | $1,647 (as of Sep 30) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% in the third quarter and 5% for the nine months ended September 30, 2007, compared to the same periods in 2006. This growth was primarily driven by a recovery in PLAVIX* sales following generic competition in 2006, as well as growth in ABILIFY*, REYATAZ, and newer products.
- Profitability Surge: Net earnings increased 154% in the third quarter and 31% for the nine months. Diluted EPS rose 153% to $0.43 in the quarter. This was significantly aided by a $247 million gain on the sale of product assets (BUFFERIN* and EXCEDRIN* brands in Japan) and lower net interest expense.
- Debt Reduction: Long-term debt decreased from $7.2 billion at December 31, 2006, to $4.2 billion at September 30, 2007. This reduction was due to the full repayment of a $1.3 billion Floating Rate Bank Term Facility and the reclassification of certain notes to short-term borrowings.
- Segment Performance: The Pharmaceuticals segment saw earnings before minority interest and income taxes increase 96% in the quarter. The Nutritionals segment earnings increased 22%, while Other Health Care increased 9%.
Guidance, Outlook, and Risks
- Strategic Transition: Management is executing a comprehensive cost reduction program involving workforce reductions and facility rationalization. The company expects to incur material restructuring charges over the next three years, though specific amounts are not yet estimable.
- Legal Proceedings (PLAVIX*): A significant risk remains regarding the patent litigation with Apotex. While a District Court upheld the patent validity in June 2007, Apotex has appealed. Loss of market exclusivity would be material to sales and cash flows. The company estimates generic competition impacted 2006 sales by $525-$600 million.
- Legal Settlements: The company finalized a settlement with the DOJ and U.S. Attorney for Massachusetts regarding pricing and marketing practices, agreeing to pay approximately $516 million (including interest). The federal portion was paid; state approval is pending.
- Acquisitions: In October 2007 (subsequent event), BMS acquired Adnexus Therapeutics for a net price of $415 million, expecting to record an in-process R&D charge of approximately $230 million in Q4 2007.
- Product Pipeline: The company received FDA approval for IXEMPRA (breast cancer) and ATRIPLA (HIV) in Canada. It is also advancing ERBITUX* in Japan and developing saxagliptin and dapagliflozin for diabetes in collaboration with AstraZeneca.
Investor Verification Checklist
- PLAVIX* Litigation Status: Verify the outcome of the Apotex appeal and the potential timeline for generic entry in the U.S. and international markets.
- Restructuring Costs: Monitor future filings for specific details on the magnitude and timing of the anticipated cost reduction program charges.
- State Settlement Approval: Confirm whether the remaining $182 million state portion of the DOJ settlement is approved and paid.
- Adnexus Integration: Review Q4 2007 results for the impact of the $230 million in-process R&D charge related to the Adnexus acquisition.
- Patent Expirations: Track the expiration dates for key products like PRAVACHOL (already expired in many markets), TAXOL, and CARDIOLITE (patent expires Jan 2008) to assess future revenue erosion.